No Severe Long-Term Toxicities With 2-Year Local Recurrence-Free Survival At 77%
Alpha Tau Medical Publishes Pooled Analysis Of Alpha DaRT Therapy In Journal *Cancers*; Data From 4 International Trials Show Nearly 100% Overall Response Rate And 89% Complete Response Rate In Treated Lesions
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.